Radiological study for vascular anomalies using AI
- Conditions
- Vascular anomalies
- Registration Number
- jRCT1040220052
- Lead Sponsor
- Michio Ozeki
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
1, A multicenter phase III investigator-initiated clinical trial (NPC-12T-LM study) conducted from 2017 to 2019 to investigate the efficacy and safety of NPC-12T (sirolimus) for intractable lymphatic disease, Multi-center, open-label, uncontrolled study to investigate the safety and efficacy of sirolimus for refractory vascular and lymphatic diseases (SRL-CVA-01 study, jRCTs031180290) started in 2017, and Conducted from 2020 to 2022, a multicenter phase III investigator-initiated clinical trial (NPC -12T-CVA) 2) Patients with evaluable MRI images 3) Patients who agreed to participate in this study
- Patients with other than obvious vascular abnormalities
- Patients with clearly different lesions and image artifacts such as bleeding and inflammation that are difficult to evaluate
- Other patients who are judged to be inappropriate by the principal investigator or co-investigator
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Correlation coefficient between lesion volumes Correlation coefficient between "lesion volume of vascular abnormalities measured by deep learning" and "lesion volume independently measured by two radiologists"
- Secondary Outcome Measures
Name Time Method Correlation coefficient (ICC(2,1)) of analysis results of area and volume measured independently by two radiologists and a trained doctor Correlation coefficient (ICC(2,1)) of analysis results of area and volume measured independently by two radiologists and a trained doctor
Differences in AI segmentation and correlation coefficients with different MRI images Differences in AI segmentation and correlation coefficients with different MRI images (fat-suppressed T2-weighted images, T1-weighted images, contrast-enhanced T1-weighted images, etc.)